ReviewDermatology practical & conceptual2026
Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review.
Review in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCDK4/6 inhibitors have revolutionized the therapeutic management of metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer (BC) by increasing treatment efficacy while maintaining a favorable safety profile. An exceedingly rare adverse event associated with these agents is the development of vitiligo-like skin depigmentation.
objectivesThis study aimed to characterize a case of ribociclib-induced vitiligo and investigate its underlying pathogenic mechanisms, with particular focus on vitiligo onset. We report the case of a 60-year-old postmenopausal female with metastatic, hormone-sensitive BC who experienced a durable partial remission during treatment with ribociclib in combination with aromatase inhibitors. During therapy, the patient developed hypopigmented lesions on her upper limbs 34 months after initiation of ribociclib, preceded by pruritus and erythema.
methodsReflectance confocal microscopy (RCM) optical coherence tomography (OCT), and histopathological examination were used.
resultRCM and OCT proved valuable for real-time assessment and monitoring of skin changes, thereby informing clinical decisions regarding the management of skin toxicity. The presence of an inflammatory infiltrate, comprising lymphocytes and hyper-reflective inflammatory cells, suggests that inhibition of the CDK4/6 pathway may enhance antitumor activity beyond cell cycle arrest by modulating the immune response and promoting immune-mediated tumor control.
conclusionsThe observed alterations in melanocyte regression could represent evidence of systemic immune activation and autoimmunity influencing melanocyte viability. These mechanisms may have significant implications for improving patient prognosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.